Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
synthetic lethality
Biotech
Repare lays off 25% of staff as biotech halts preclinical R&D
The biotech is scaling back preclinical work to focus on more advanced candidates such as a synthetic lethal drug handed back by Roche in February.
James Waldron
Aug 29, 2024 6:36am
Ideaya bags option on Biocytogen bispecific ADC in $400M deal
Jul 31, 2024 9:04am
Tango drops USP1 inhibitor over liver toxicity in phase 1 trial
May 23, 2024 8:11am
Roche axes Repare's oncology drug days after starting study
Feb 13, 2024 5:51am
Merck inks $169M PARP1 deal, escalating challenge to AstraZeneca
Oct 30, 2023 8:40am
Day One jets off with Sprint's VRK1 program for up to $316M
Aug 16, 2023 10:47am